In The News
06/2010 InVivo/Start-Up Magazine: Enhancing Tissue Oxygen Levels for Clinical Benefit
InVivo/Start-Up article. Deep thinking about nature has long inspired scientific achievement. Centuries after Leonardo daVinci sketched a plan for a helicopter after musing on a dragonfly, the founders of NormOxys Inc. are working to commercialize molecules similar to those that give migratory birds the fortitude to fly thousands of miles.
06/2010 NormOxys, Inc., Appoints Biotech Veteran as Head of Preclinical Research & Development
WELLESLEY, MA - June 21, 2010 - NormOxys, Inc., today announced that John A. Hey, Ph.D., has been appointed Senior Vice President of Preclinical and Early Development.
05/2010 The Pink Sheet Daily: Privately Held NormOxys Raises $17.5 Million Series B
The Pink Sheet Daily article. NormOxys, which is developing small molecule oxygen-enhancing drugs to treat a variety of diseases, announced May 24 a $17.5 million Series B financing.
05/2010 BioWorld Today: NormOxys Gets $17.5M Series B to Fund Cardio, Cancer Studies
BioWorld Today article. After gathering encouraging preclinical data on its oxygen-boosting small molecules, NormOxys Inc. raised $17.5 million in a Series B-1 financing to push its programs to proof of concept in chronic heart failure and cancer.
05/2010 Xconomy: NormOxys Pockets $17.5M for Drugs Against Heart Failure, Cancer
Xconomy article. NormOxys, the Wellesley, MA-based company on a quest to make a new class of drugs that normalize oxygen levels in deprived tissues, has raised $17.5 million in venture capital to run its first set of tests in people with chronic heart failure and cancer.
05/2010 NormOxys, Inc. Initiates Phase I Clinical Trial
WELLESLEY, MA - May 24, 2010 - NormOxys, Inc. today announced that it has initiated a Phase I clinical trial of OXY111A, a novel allosteric modulator of the affinity of hemoglobin for oxygen.
05/2010 NormOxys, Inc. Secures $17.5 million Series B Financing
WELLESLEY, MA - May 24, 2010 - NormOxys, Inc. today announced it has raised $17.5 million in a Series B financing round.
01/2010 BioWorld Today: More Oxygen, Please
BioWorld Today article. More Oxygen, Please: NormOxys Targeting Disease via Hypoxia.
12/2009 NormOxys, Inc. Appoints First Chief Medical Officer
WELLESLEY, MA - December 14, 2009 - NormOxys, Inc. announced today the appointment of David Clark, MD, as its first Chief Medical Officer.
12/2009 BioCentury: Setting Oxygen Free
BioCentury article. NormOxys is preparing to enter the clinic with oxyren small molecules, which enhance hemoglobin's ability to release oxygen in hypoxia-related indications like cancer and congestive heart failure.
12/2009 Xconomy: NormOxys Emerges from Stealth with New Class of Oxygen Drugs for Cancer, Heart Failure
Xconomy article. Everyone needs oxygen, and major health problems can pop up when certain tissues get too little or too much.
12/2009 NormOxys Appoints Industry Veteran as CEO
WELLESLEY, MA - December 4, 2009 NormOxys. Inc. today announced that it has appointed Martin Tolar, MD, PhD, as the company's President and Chief Executive Officer.
04/2009 NormOxys Secures Series B Financing
BOSTON, MA - April 22, 2009 - NormOxys today announced that it has secured the first tranche of $4.5 million in Series B financing.
11/2008 NormOxys Appoints Jean-Pierre Garnier, PhD, to Board of Directors
BOSTON, MA - November 5, 2008 - NormOxys, Inc., announced today the appointment of Jean-Pierre Garnier, PhD, as Chairman of its Board of Directors.
08/2007 NormOxys Announces Series A Financing
BOSTON, MA - August 31, 2007 - NormOxys, Inc., today announced that it has secured a Series A financing of $8 million.